Cerus Corp
CERS1.285USD
+0.015+1.18%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
245.58MCap. mercado
PérdidaP/E TTM
Más Datos de Cerus Corp Compañía
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Información de la empresa
Símbolo de cotizaciónCERS
Nombre de la empresaCerus Corp
Fecha de salida a bolsaJan 31, 1997
Director ejecutivoMr. William M. (Obi) Greenman
Número de empleados281
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección1220 Concord Avenue
CiudadCONCORD
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94520
Teléfono19252886000
Sitio Webhttps://www.cerus.com/
Símbolo de cotizaciónCERS
Fecha de salida a bolsaJan 31, 1997
Director ejecutivoMr. William M. (Obi) Greenman
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
304.17K
+24.57%
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
289.70K
-64.05%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
182.05K
+49.16%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
131.10K
+84.39%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Jami K. Nachtsheim ,
Jami K. Nachtsheim ,
Independent Director
Independent Director
--
--
Mr. Dean A. Gregory
Mr. Dean A. Gregory
Director
Director
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Richard J. Benjamin, Ph.D.
Dr. Richard J. Benjamin, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Timothy L. (Tim) Moore
Mr. Timothy L. (Tim) Moore
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
304.17K
+24.57%
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
289.70K
-64.05%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
182.05K
+49.16%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
131.10K
+84.39%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Jami K. Nachtsheim ,
Jami K. Nachtsheim ,
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Product
43.24M
0.00%
Por regiónUSD
Nombre
Ganancia
Proporción
North America
30.60M
70.77%
Europe and Middle East and Africa
12.21M
28.24%
Other
427.00K
0.99%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product
43.24M
0.00%
Estadísticas de accionistas
Actualizado: jue., 22 de may
Actualizado: jue., 22 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
10.12%
ARK Investment Management LLC
10.05%
BlackRock Institutional Trust Company, N.A.
6.77%
The Vanguard Group, Inc.
5.52%
Wasatch Global Investors Inc
4.35%
Other
63.19%
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
10.12%
ARK Investment Management LLC
10.05%
BlackRock Institutional Trust Company, N.A.
6.77%
The Vanguard Group, Inc.
5.52%
Wasatch Global Investors Inc
4.35%
Other
63.19%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
29.51%
Hedge Fund
20.42%
Investment Advisor/Hedge Fund
20.22%
Individual Investor
4.69%
Research Firm
3.80%
Family Office
1.22%
Venture Capital
0.10%
Bank and Trust
0.09%
Pension Fund
0.07%
Other
19.86%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
330
149.69M
78.31%
-11.42M
2025Q1
349
154.49M
80.95%
-4.85M
2024Q4
362
150.65M
81.09%
-18.33M
2024Q3
373
152.20M
82.15%
-11.01M
2024Q2
387
150.50M
81.41%
-12.83M
2024Q1
386
146.19M
80.62%
-12.96M
2023Q4
385
141.79M
78.32%
-24.31M
2023Q3
382
146.35M
81.02%
-13.17M
2023Q2
384
145.73M
80.79%
-19.32M
2023Q1
387
151.80M
85.48%
-8.28M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Baker Bros. Advisors LP
19.35M
10.12%
-126.25K
-0.65%
Mar 31, 2025
ARK Investment Management LLC
20.66M
10.81%
-159.61K
-0.77%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
12.94M
6.77%
+28.20K
+0.22%
Mar 31, 2025
The Vanguard Group, Inc.
10.55M
5.52%
+137.20K
+1.32%
Mar 31, 2025
Wasatch Global Investors Inc
8.32M
4.35%
--
--
Mar 31, 2025
Nikko Asset Management Co., Ltd.
6.19M
3.24%
-270.80K
-4.19%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.54M
2.38%
+87.67K
+1.97%
Mar 31, 2025
Senvest Management, LLC
4.41M
2.3%
-1.99M
-31.10%
Mar 31, 2025
State Street Global Advisors (US)
3.80M
1.99%
-8.14K
-0.21%
Mar 31, 2025
D. E. Shaw & Co., L.P.
3.79M
1.98%
+361.80K
+10.55%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ARK Genomic Revolution ETF
0.94%
Invesco NASDAQ Future Gen 200 ETF
0.5%
ARK Innovation ETF
0.23%
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.04%
iShares US Small-Cap Equity Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Ver más
ARK Genomic Revolution ETF
Proporción0.94%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.5%
ARK Innovation ETF
Proporción0.23%
iShares Micro-Cap ETF
Proporción0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.05%
Fidelity Enhanced Small Cap ETF
Proporción0.04%
iShares US Small-Cap Equity Factor ETF
Proporción0.04%
iShares Russell 2000 Growth ETF
Proporción0.02%
Global X Russell 2000 ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
